Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them.

The 64th ASH Annual Meeting and Exposition is a four-day premier event in malignant and non-malignant hematology, scheduled to start on December 10, 2022. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few major abstracts for diffuse large B-cell lymphoma (DLBCL).

The key abstracts have been summarized in the table below:

Drug regimen

Abstract ID

Abstract Title

Trial ID

Company

Class

Tafasitamab + Lenalidomide + R-CHOP

2947

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

NCT04824092

(frontMIND)

MorphoSys AG

CD19-directed monoclonal antibody

Odronextamab

444

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

NCT03888105

(ELM-2)

Regeneron Pharmaceuticals

Bispecific antibody

Loncastuximab Tesirine + Rituximab

2955

A Phase II, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)

NCT05144009 (LOTIS-9)

ADC Therapeutics

Antibody Drug Conjugate (ADC)

Epcoritamab + R-DHAX/C

443

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase I/II Results

NCT04663347

(EPCORE NHL-2)

Genmab/AbbVie

Bispecific antibody

Mosunetuzumab

738

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

NCT03677154

Roche

Bispecific antibody

Axicabtagene Ciloleucel  + Lenzilumab

4635

ZUMA-19: A Phase I/II Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

NCT04314843 (ZUMA-19)

Gilead Sciences

CAR-T cell therapy

Iberdomide ± Anti-CD20

233

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase I/II Study

NCT04464798

BMS

Immunomodulatory imide drug (IMiDs)

Tafasitamab + Lenalidomide + R‑CHOP

1619

First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04134936

(First-MIND)

MorphoSys AG

CD19-directed monoclonal antibody

Glofitamab + R-CHOP

737

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

NCT03467373

Roche

Bispecific antibody

YTB323

439

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

NCT03960840

Novartis Pharmaceuticals

CAR-T cell therapy